ATE221915T1 - Identifizierung eines menschlichen rezeptor- tyrosinkinasegens - Google Patents

Identifizierung eines menschlichen rezeptor- tyrosinkinasegens

Info

Publication number
ATE221915T1
ATE221915T1 AT92907369T AT92907369T ATE221915T1 AT E221915 T1 ATE221915 T1 AT E221915T1 AT 92907369 T AT92907369 T AT 92907369T AT 92907369 T AT92907369 T AT 92907369T AT E221915 T1 ATE221915 T1 AT E221915T1
Authority
AT
Austria
Prior art keywords
receptor
receptor tyrosine
tyrosine kinase
identification
kinase gene
Prior art date
Application number
AT92907369T
Other languages
English (en)
Inventor
Bruce Israel Terman
Miguel Eduardo Carrion
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE221915T1 publication Critical patent/ATE221915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
AT92907369T 1991-02-22 1992-02-20 Identifizierung eines menschlichen rezeptor- tyrosinkinasegens ATE221915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65723691A 1991-02-22 1991-02-22
PCT/US1992/001300 WO1992014748A1 (en) 1991-02-22 1992-02-20 Identification of a novel human receptor tyrosine kinase gene

Publications (1)

Publication Number Publication Date
ATE221915T1 true ATE221915T1 (de) 2002-08-15

Family

ID=24636385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907369T ATE221915T1 (de) 1991-02-22 1992-02-20 Identifizierung eines menschlichen rezeptor- tyrosinkinasegens

Country Status (8)

Country Link
EP (1) EP0536350B1 (de)
AT (1) ATE221915T1 (de)
CA (1) CA2083401C (de)
DE (1) DE69232718T2 (de)
DK (1) DK0536350T3 (de)
ES (1) ES2180535T3 (de)
SG (1) SG49753A1 (de)
WO (1) WO1992014748A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU3482493A (en) * 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
BR9207175A (pt) * 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
DK0694042T3 (da) * 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
IL124728A (en) * 1995-12-18 2007-06-03 Sugen Inc AURORA – 1 and AURORA – 2 proteins
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
DE69838334T2 (de) * 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
CA2345276C (en) 1998-10-09 2011-03-29 Ludwig Institute For Cancer Research Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6416758B1 (en) 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2002011769A1 (en) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
PT2949658T (pt) 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
RU2005136988A (ru) 2003-05-30 2006-06-10 Дженентек, Инк. (Us) Лечение антителами против vegf
CA2590671A1 (en) 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
DK2956476T3 (da) 2013-02-18 2020-02-17 Vegenics Pty Ltd Ligandbindende molekyler og anvendelser deraf

Also Published As

Publication number Publication date
ES2180535T3 (es) 2003-02-16
EP0536350A4 (de) 1994-03-22
DE69232718T2 (de) 2003-04-03
DE69232718D1 (de) 2002-09-12
WO1992014748A1 (en) 1992-09-03
EP0536350B1 (de) 2002-08-07
EP0536350A1 (de) 1993-04-14
SG49753A1 (en) 1998-06-15
CA2083401C (en) 2003-03-25
CA2083401A1 (en) 1992-08-23
DK0536350T3 (da) 2002-09-02

Similar Documents

Publication Publication Date Title
ATE221915T1 (de) Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
EA199800116A1 (ru) Пирролопиримидины и фармацевтические композиции, включающие эти соединения
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
BRPI0009721B8 (pt) Inibidores de tirosina quinase de proteína cíclica
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
ATE324441T1 (de) Htk-ligand
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
CA2079585A1 (en) Ligand for the neu gene product
BR0209425A (pt) Molécula de ácido nucleico isolada, célula hospedeira, polipeptìdeo isolado, anticorpo, métodos para produzir um polipeptìdeo e para detectar a presença de um polipeptìdeo e de uma molécula de ácido nucleico, kit, métodos para produzir acetaldeìdo e etanol, extrato de enzima, método para selecionar uma enzima de piruvato descarbixilase, e, plasmìdeo
TR200100074T2 (tr) Nevrotrofik büyüme faktörü
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
DK0418797T3 (da) Pyrimidin-4,6-dicarboxylsyrediamider, fremgangsmåde til deres fremstilling, deres anvendelse samt lægemiddel på basis af disse forbindelser
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE69129034T3 (de) Molekulare klone von hiv-1 und deren verwendung
ATE417930T1 (de) Proteinkinase npk-110
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
ATE271125T1 (de) Neuartige tyrosinkinase
DE69233330D1 (de) Verwendung eines Inhibitors von Tau/Neurofilament-Proteinkinase PK40
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
DE59207008D1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
BG103342A (en) Gax protein domains-containing polypeptides included in the presented transcription and/or interrelated to other proteins corresponding to neucleinic acids, and their application
SE9604439D0 (sv) New receptor
Bazari STUDIES ON CALMODULIN FROM DICTYOSTELIUM DISCOIDEUM.
YU46928B (sh) Postupak za dobijanje novog proteina sa osobinama čovečijeg stefina b i njegovih mutanata

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0536350

Country of ref document: EP

REN Ceased due to non-payment of the annual fee